Improving patient outcome by fluid optimization guided by the CardioQTM has been demonstrated to result in significant cost savings due to the patients leaving hospital quicker and in better condition than they would otherwise.
The clinical literature contains over 70 published clinical trials using the Deltex Medical Oesophageal Doppler Technology of the CardioQTM. This literature reports an average reduction in hospital stay of in excess of 33%. The savings in hospital stay range from 19% to as high as 44%.
Depending on the management strategies in place, these savings could be directed to reducing waiting lists, or decreasing occupancy or reinvested in surgical care beds to improve post operative care. A formal post-procurement review by Medway NHS Trust (the ``Trust``) on the impact of the wide scale use of Deltex Medical`s CardioQTM system was carried out early in 2004. The Trust`s conclusion was that the average reductions in length of hospital stay of approximately two days per patient across a wide range of surgical procedures could be attributed directly to the use of the CardioQTM.
As a result, the Trust has stated that its managers, anaesthetists and surgeons will now work together to ensure that the use of the CardioQTM is established as a standard of care on as many as possible of the 7,500 moderate and major risk surgical patients treated by the Trust each year. This Trust is therefore able to quickly improve clinical outcomes whilst benefiting from significantly better economic performance by using the CardioQTM system.
Deltex Medical is willing to continue to work with its customers to help demonstrate the level of cost savings made in the hospitals using a number of tools that we have developed.
